Menu Search
Equities

United Laboratories International Holdings Ltd

3933:HKG

United Laboratories International Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)9.85
  • Today's Change-0.31 / -3.05%
  • Shares traded2.52m
  • 1 Year change+23.28%
  • Beta0.5902
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in CNY

The 5 analysts offering 12 month price targets for The United Laboratories Intl. Hldgs Ltd. have a median target of 11.22, with a high estimate of 15.01 and a low estimate of 9.32. The median estimate represents a 13.87% increase from the last price of 9.85.
High52.4%15.01
Med13.9%11.22
Low-5.3%9.32

Dividends

In 2023, United Laboratories International Holdings Ltd reported a dividend of 0.40 CNY, which represents a 114.72% increase over last year. The 3 analysts covering the company expect dividends of 0.11 CNY for the upcoming fiscal year, a decrease of 72.37%.
Div growth (TTM)114.72%
More ▼

Earnings history & estimates in CNY

The United Laboratories Intl. Hldgs Ltd. reported annual 2023 earnings of 1.49 per share on Mar 26, 2024.
Average growth rate+42.16%
More ▼

Revenue history & estimates in CNY

The United Laboratories International Holdings Limited had revenues for the full year 2023 of 13.74bn. This was 21.22% above the prior year's results.
Average growth rate+13.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.